The FDA approved Dendreon's immunotherapy Provenge for the treatment of certain men with advanced prostate cancer, marking the first approval of a vaccine to treat cancer. Karen Midthun, acting director of the FDA’s Center for Biologics Evaluation and Research said the autologous cellular immunotherapy "provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available.”
Source
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment